The recognition promoted by PNICube, which since 2007 has rewarded the startups of the circuit that are achieving the best performance on the markets, was conferred today at the University of Rome “Tor Vergata”.
Rome, 17 May 2019
This morning, Bioscience Genomics – a spin-off of the University of Rome “Tor Vergata” founded in 2014 – won the 13th edition of the Award for young hi-tech companies generated by academic research.
The Italian Master Startup Award – promoted by the Italian Association of University Incubators PNICube and organized this year by the University of Rome “Tor Vergata”, through the CTiF (Center for Teleinfrastructure) operational headquarters of StartCup Lazio, with the collaboration of the Inuit Foundation and the main partner Almaviva – it is the only award on a national basis that recognizes the actual results achieved by startups born from academic research in their first years of life, at the same time creating an important bridge with the world of investors.
The award ceremony – which was held in the Faculty of Economics of the University of Rome “Tor Vergata” – was preceded by a round table on the theme “Sustainability, Innovation and Startups” and by the pitches of the 14 finalist startups, all with a high technological impact, who illustrated the progress made and future objectives to a qualified jury composed of investment fund operators, early-stage financing specialists and business managers.
“The 2019 edition of IMSA awarded one of the leading sectors of the Italian scientific research, genomics – commented Giovanni Perrone, President of PNICube – The Bioscience Genomics award testifies to the attention of the ecosystem of innovative entrepreneurship towards applications of research to problems of great social interest. The 2019 edition of IMSA placed particular emphasis on further strengthening the dialogue between university startups and the world of investors.”
BIOSCIENCE GENOMICS [https://bioinst.com] is a spin-off of the University of Rome “Tor Vergata”, with offices in Rome and Milan, and offers services in the field of genomics. Taking advantage of the most recent new generation sequencing technologies, it analyzes circulating free DNA, both for the evaluation of any fetal anomalies during a pregnancy, and for the evaluation of somatic mutations for oncological prevention. The initial reference market is the Italian one, where the company is developing services in the cancer prevention sector, after having thoroughly explored the specialist area of obstetrics. The team, made up of 15 people, including 10 biologists, is led in Rome by Branch Manager Alessandra Tacconelli. “Expanding the market abroad, finding new methodologies for cancer prevention and identifying new areas of application for Next Generation Sequencing (NGS) are our next challenges,” she said.